Can a personalized drug strategy wipe out hidden myeloma cells?

NCT ID NCT04140162

Ongoing Disease control Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a combination of daratumumab, lenalidomide, and dexamethasone, followed by a stronger regimen if needed, can make multiple myeloma undetectable at a deep level (MRD-negative) in newly diagnosed patients. The treatment plan adapts based on each person's response, with additional drugs given only if cancer cells remain after initial therapy. The goal is to see if this tailored approach leads to better remission rates than standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: daratumumab, lenalidomide, dexamethasone, bortezomib
What this could lead to: If successful, this approach could lead to more patients achieving deep remission (MRD-negative status) and potentially better long-term outcomes for newly diagnosed multiple myeloma.
What could go wrong: This is a phase 2 trial with a small number of participants, so results may not apply broadly. The adaptive design means not all patients receive the same treatment, and side effects from the drug combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109, United States
University of Rochester

Rochester, New York, 14642, United States
University of Texas Southwestern -- Simmons Comprehensive Cancer Center

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.